Slide 1: AngioDynamics Second Quarter 2023 Earnings Presentation
ANGIODYNAMICS Second Quarter 2023 Earnings Presentation January 5, 2023 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q2 and YTD FY23 Highlights
Corporate Developments – Q2 and YTD FY23 Highlights Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife Operational highlights Gross margin improvements partially offset by continued headwinds in the supply chain, labor shortages, freight and inflati
Slide 4: Q2 and YTD FY23 Results (unaudited)
Q2 and YTD FY23 Results (unaudited) $ in thousands (except per share data) Q2 FY23 Q2 FY22 Change YTD FY23 YTD FY22 Change Revenue $85,429 $78,280 9.1% $166,966 $155,251 7.5% Med Tech Med Device $24,502 $60,927 $18,886 $59,394 29.7% 2.6% $47,318 $119,648 $36,493 $118,758 29.7% 0.7% United States Int
Slide 5: Q2 and YTD FY23 Highlights
Q2 and YTD FY23 Highlights 5 Med Device Med Tech 29.7% growth 0.7% growth YTD Revenue Growth YTD FY22 YTD FY23 YTD Revenue Contribution YTD FY22 YTD FY23 Med Device Med Tech 29.7% growth 2.6% growth Q2 Revenue Growth Q2 FY22 Q2 FY23 Q2 Revenue Contribution Q2 FY22 Q2 FY23
Slide 6: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods 6 Med Tech Q2 FY23 YTD FY23 Auryon 60.6% 55.5% Thrombus Management* AngioVac AlphaVac** (0.3%) (16.2%) 205.3% 14.5% (4.6%) N/A NanoKnife® Disposables 45.4% 28.9% NanoKnife® Capital 64.1% 1.5% Med Device Q2 FY23 YTD FY23 Solero® Microwave 7.0% 6.6% BioSentry (8.
Slide 7: FY23 Guidance
FY23 Guidance 7 FY23 Guidance Reaffirmed Q4 FY2022 Revenue $342 - $348 million Gross Margin Med Tech Med Device 52.5% - 54.5% 65% - 68% 45% - 48% Adjusted EPS $0.01 - $0.06
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustment to re